The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 25, 2016

Filed:

Nov. 21, 2012
Applicant:

Abbvie Deutschland Gmbh & Co. KG, Wiesbaden, DE;

Inventors:

Astrid Netz, Mannheim, DE;

Wilhelm Amberg, Mannheim, DE;

Udo Lange, Mannheim, DE;

Michael Ochse, Bad Durkheim, DE;

Charles W. Hutchins, Green Oaks, IL (US);

Francisco-Xavier Garcia-Ladona, Kandel, DE;

Wolfgang Wernet, Neustadt, DE;

Andreas Kling, Mannheim, DE;

Assignee:
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07D 277/48 (2006.01); C07D 277/82 (2006.01); C07D 333/36 (2006.01); C07D 263/48 (2006.01); C07D 277/60 (2006.01); C07D 235/30 (2006.01); C07D 513/04 (2006.01); C07D 417/12 (2006.01); C07D 417/04 (2006.01); C07D 231/56 (2006.01); C07D 237/22 (2006.01); C07D 249/14 (2006.01); C07D 261/14 (2006.01); C07D 263/28 (2006.01); C07D 285/08 (2006.01); C07D 285/135 (2006.01);
U.S. Cl.
CPC ...
C07D 263/48 (2013.01); C07D 231/56 (2013.01); C07D 235/30 (2013.01); C07D 237/22 (2013.01); C07D 249/14 (2013.01); C07D 261/14 (2013.01); C07D 263/28 (2013.01); C07D 277/48 (2013.01); C07D 277/60 (2013.01); C07D 277/82 (2013.01); C07D 285/08 (2013.01); C07D 285/135 (2013.01); C07D 333/36 (2013.01); C07D 417/04 (2013.01); C07D 417/12 (2013.01); C07D 513/04 (2013.01);
Abstract

The present invention relates to guanidine compounds of the general formula I corresponding enantiomeric, diastereomeric and/or tautomeric forms thereof as well as pharmaceutically acceptable salts thereof. The present compound further relates to the use of guanidine compounds as binding partners for 5-HT5 receptors for the treatment of diseases which are modulated by a 5-HT5 receptor activity, in particular for the treatment of neurodegenerative and neuropsychiatric disorders as well as the associated signs, symptoms and dysfunctions.


Find Patent Forward Citations

Loading…